Equities Analysts Issue Forecasts for AbbVie FY2027 Earnings

AbbVie Inc. (NYSE:ABBV) – Equities research analysts at Erste Group Bank lifted their FY2027 earnings per share estimates for AbbVie in a research note issued to investors on Tuesday, March 24th. Erste Group Bank analyst H. Engel now forecasts that the company will post earnings of $16.16 per share for the year, up from their previous estimate of $16.11. The consensus estimate for AbbVie’s current full-year earnings is $12.31 per share.

Several other equities analysts have also recently issued reports on ABBV. Barclays began coverage on shares of AbbVie in a research report on Thursday, February 19th. They set an “overweight” rating and a $275.00 price target on the stock. BMO Capital Markets restated an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a research report on Thursday, February 5th. The Goldman Sachs Group reiterated a “neutral” rating and set a $223.00 target price on shares of AbbVie in a report on Wednesday, January 28th. Finally, Royal Bank Of Canada began coverage on AbbVie in a research report on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $253.15.

AbbVie Trading Up 1.9%

Shares of NYSE ABBV opened at $211.12 on Thursday. The firm has a fifty day simple moving average of $222.06 and a two-hundred day simple moving average of $224.53. AbbVie has a 12 month low of $164.39 and a 12 month high of $244.81. The firm has a market capitalization of $373.29 billion, a PE ratio of 89.46, a price-to-earnings-growth ratio of 0.72 and a beta of 0.34.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The company had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The firm’s revenue was up 10.0% on a year-over-year basis. During the same quarter last year, the firm posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is 293.22%.

Insider Transactions at AbbVie

In related news, EVP Perry C. Siatis sold 22,381 shares of the business’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares of the company’s stock, valued at $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares in the company, valued at approximately $619,868.24. This trade represents a 66.34% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 0.25% of the company’s stock.

Institutional Trading of AbbVie

Hedge funds and other institutional investors have recently made changes to their positions in the stock. J. Derek Lewis & Associates Inc. bought a new stake in shares of AbbVie in the 4th quarter worth $4,173,000. Purpose Unlimited Inc. bought a new position in shares of AbbVie during the fourth quarter valued at $172,000. Stance Capital LLC boosted its position in shares of AbbVie by 1.4% during the fourth quarter. Stance Capital LLC now owns 6,240 shares of the company’s stock valued at $1,426,000 after buying an additional 86 shares during the last quarter. Cornerstone Planning LLC purchased a new stake in shares of AbbVie during the fourth quarter valued at $3,421,000. Finally, Rockefeller Capital Management L.P. increased its holdings in AbbVie by 10.1% in the 4th quarter. Rockefeller Capital Management L.P. now owns 883,644 shares of the company’s stock worth $201,904,000 after buying an additional 81,375 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Allergan Aesthetics will present 21 evidence-based e-posters at AMWC 2026, highlighting clinical and real‑world data that support product leadership and could help maintain premium pricing and practitioner demand. Allergan Aesthetics Reinforces Scientific Differentiation and Leadership with 21 Evidence-Based E-Posters at the 2026 Aesthetic & Anti-Aging Medicine World Congress (AMWC)
• Positive Sentiment: Allergan is promoting a new “Undetectable” era for JUVÉDERM at AMWC, a marketing/product push that may support volume and pricing for AbbVie’s largest aesthetics franchise. Allergan Aesthetics Ushers in a New Age of Hyaluronic Acid (HA) Injectables with JUVÉDERM® at AMWC Monaco
• Positive Sentiment: Erste Group nudged up its FY2027 EPS forecast for AbbVie (to $16.16), a small analyst lift that signals growing analyst confidence in longer‑term earnings power. Erste Group Bank upped their FY2027 earnings per share (EPS) estimates for AbbVie
• Positive Sentiment: AbbVie’s official partnership with MLB (seasonal marketing/awareness) can broaden brand visibility for patient and provider audiences and is a supportive commercial catalyst. How AbbVie’s official partnership with MLB will unfold over the course of the season
• Neutral Sentiment: Zacks and other outlets note elevated investor attention on AbbVie and publish comparative takes (e.g., vs. Eli Lilly) — increased search/coverage can raise short-term volatility but also liquidity. Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
• Neutral Sentiment: Coverage labeling AbbVie as a candidate in the psychedelics/psychiatry theme (coverage of bretisilocin acquisition) may attract growth‑oriented investors, but clinical risk and long timelines keep impact uncertain. Is AbbVie (ABBV) one of the Best Psychedelic Stocks to Buy in 2026?
• Negative Sentiment: Analyst commentary and valuation pieces point to recent share weakness (declines over the past week/month) and ongoing valuation questions despite multi-year gains, which can cap near‑term upside. Is AbbVie (ABBV) Now Offering Value After Recent Share Price Weakness?

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.